Trial reportHeart (British Cardiac Society)2000
Endogenous endothelin maintains coronary artery tone by endothelin type A receptor stimulation in patients undergoing coronary arteriography.
Trial report in Heart (British Cardiac Society), 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 46 citations in OpenAlex.
- Long-term endothelin receptor antagonism attenuates coronary plaque progression in patients with early atherosclerosis.International journal of cardiology · 2013Trial
- Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis.Circulation · 2010Trial
- Selective endothelin A-receptor blockade attenuates coronary microvascular dysfunction after coronary stenting in patients with type 2 diabetes.Vascular health and risk management · 2009Trial
- Coronary Artery Spasm: From Physiopathology to Diagnosis.Life (Basel, Switzerland) · 2025Review
- Updates on Pharmacologic Management of Microvascular Angina.Cardiovascular therapeutics · 2022Review
- Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial.American heart journal · 2020Article
- The Biochemical Markers Associated with the Occurrence of Coronary Spasm.BioMed research international · 2019Review
- HIV infection and cocaine use induce endothelial damage and dysfunction in African Americans.International journal of cardiology · 2012Article
- Role of inflammation in the regulation of coronary blood flow in ischemia and reperfusion: mechanisms and therapeutic implications.Journal of molecular and cellular cardiology · 2012Review
- Working under pressure: coronary arteries and the endothelin system.American journal of physiology. Regulatory, integrative and comparative physiology · 2010Review
- Endothelium-derived endothelin-1.Pflugers Archiv : European journal of physiology · 2010Review
- Impairment of coronary endothelial cell ET(B) receptor function after short-term inhalation exposure to whole diesel emissions.American journal of physiology. Regulatory, integrative and comparative physiology · 2009Article
- The importance of endothelin-1 for microvascular dysfunction in diabetes.Vascular health and risk management · 2008Review
- Elevated endothelin-1 levels are associated with decreased arterial elasticity in hypertensive patients.Journal of clinical hypertension (Greenwich, Conn.) · 2006Article
- Vasoconstrictor activity of novel endothelin peptide, ET-1(1 - 31), in human mammary and coronary arteries in vitro.British journal of pharmacology · 2001Article
- Physiological antagonism of endothelin-1 in human conductance and resistance coronary artery.British journal of pharmacology · 2001Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine the contribution of endothelin type A (ET(A)) receptor stimulation by endogenously generated endothelin-1 (ET-1) to the maintenance of coronary vascular tone in humans.
designControlled clinical study.
settingTertiary cardiovascular referral centre. PATIENTS: 14 subjects were studied, seven with normal coronary arteries and seven with coronary artery disease, mean (SEM) age, 53 (2) years.
interventionsAfter diagnostic coronary arteriography, BQ-123 (a selective ET(A) receptor antagonist; 100 nmol/min) in 0.9% saline, was infused into the left coronary artery at a rate of 1 ml/min for 60 minutes. Eight control subjects received saline alone.
main outcome measuresBlood flow velocity in the left anterior descending coronary artery, measured using a Doppler flow guidewire; coronary arteriography performed at baseline and immediately at the end of the BQ-123 or saline infusion to measure the diameter of proximal and distal left anterior descending coronary artery segments.
resultsThe diameter of the proximal segment increased by 6 (2)%, while that of the distal segment increased by 12 (3)% after BQ-123 (both p < 0.05 v baseline). Coronary blood flow increased from 75 (10) to 92 (10) ml/min and coronary vascular resistance decreased from 1.99 (0.36) to 1.44 (0. 22) mm Hg/ml/min after BQ-123 (both p < 0.05 v baseline). The response to BQ-123 of patients with and without coronary artery disease was similar. There was no effect of saline in the controls.
conclusionsEndogenously produced ET-1 contributes to the maintenance of basal coronary artery tone in humans by ET(A) receptor stimulation. The role of ET(B) receptors remains to be defined.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.